notesum.ai

Published at October 28

Multi-modal AI for comprehensive breast cancer prognostication

cs.SD

cs.AI

cs.LG

eess.AS

Released Date: October 28, 2024

Authors: Jan Witowski, Ken Zeng, Joseph Cappadona, Jailan Elayoubi, Elena Diana Chiru, Nancy Chan, Young-Joon Kang, Frederick Howard, Irina Ostrovnaya, Carlos Fernandez-Granda, Freya Schnabel, Ugur Ozerdem, Kangning Liu, Zoe Steinsnyder, Nitya Thakore, Mohammad Sadic, Frank Yeung, Elisa Liu, Theodore Hill, Benjamin Swett, Danielle Rigau, Andrew Clayburn, Valerie Speirs, Marcus Vetter, Lina Sojak, Simone Muenst Soysal, Daniel Baumhoer, Khalil Choucair, Yu Zong, Lina Daoud, Anas Saad, Waleed Abdulsattar, Rafic Beydoun, Jia-Wern Pan, Haslina Makmur, Soo-Hwang Teo, Linda Ma Pak, Victor Angel, Dovile Zilenaite-Petrulaitiene, Arvydas Laurinavicius, Natalie Klar, Brian D. Piening, Carlo Bifulco, Sun-Young Jun, Jae Pak Yi, Su Hyun Lim, Adam Brufsky, Francisco J. Esteva, Lajos Pusztai, Yann LeCun, Krzysztof J. Geras

Arxiv: https://arxiv.org/abs/2410.21256v1

	Category	Training cohorts (N=4,659)	Evaluation cohorts(N=3,502)
Age median, [IQR]		58 [49-68]	60 [51-68]
Follow-up time median, [IQR]		5.11 [3.62-8.31]	4.51 [2.42-7.15]
ER receptor status
	Positive	3748 (80.45%)	2992 (85.44%)
	Negative	540 (11.59%)	399 (11.39%)
	Unknown	371 (7.96%)	111 (3.17%)
PR receptor status
	Positive	2676 (57.44%)	2648 (75.61%)
	Negative	1010 (21.68%)	728 (20.79%)
	Unknown	973 (20.88%)	126 (3.60%)
HER2 receptor status
	Positive	377 (8.09%)	348 (9.94%)
	Negative	3286 (70.53%)	2702 (77.16%)
	Equivocal or Unknown	996 (21.38%)	452 (12.91%)
T stage
	T1	1880 (40.35%)	1869 (53.37%)
	T2	1780 (38.21%)	1287 (36.75%)
	T3	252 (5.41%)	225 (6.42%)
	T4	51 (1.09%)	40 (1.14%)
	Unknown/TX	464 (9.96%)	81 (2.31%)
N stage
	N0	2550 (54.73%)	2284 (65.22%)
	N1	1174 (25.20%)	839 (23.96%)
	N2	251 (5.39%)	156 (4.45%)
	N3	141 (3.03%)	86 (2.46%)
	Unknown/NX	543 (11.65%)	137 (3.91%)
Ductal histology
	Yes	3567 (76.56%)	1392 (39.75%)
	No	904 (19.40%)	377 (10.77%)
	Unknown	188 (4.04%)	1733 (49.49%)
Lobular histology
	Yes	600 (12.88%)	359 (10.25%)
	No	3871 (83.09%)	1410 (40.26%)
	Unknown	188 (4.04%)	1733 (49.49%)
Any recurrence
	Yes	726 (15.58%)	279 (7.97%)
	No	3933 (84.42%)	3223 (92.03%)
Distant recurrence
	Yes	457 (9.81%)	174 (4.97%)
	No	4098 (87.96%)	3328 (95.03%)
	Unknown	104 (2.23%)	0 (0.00%)
Death
	Yes	935 (20.07%)	303 (8.65%)
	No	3710 (79.63%)	3199 (91.35%)
	Unknown	14 (0.30%)	0 (0.00%)
Adjuvant chemo- and endocrine therapy
	Chemoendocrine therapy	1124 (24.13%)	768 (21.93%)
	Chemotherapy only	564 (12.11%)	500 (14.28%)
	Endocrine therapy only	1551 (33.29%)	1442 (41.18%)
	Unknown	729 (15.65%)	368 (10.51%)